CN115281180A - 一种mRNA-血小板复合物冻存液及其制备方法 - Google Patents
一种mRNA-血小板复合物冻存液及其制备方法 Download PDFInfo
- Publication number
- CN115281180A CN115281180A CN202210779953.7A CN202210779953A CN115281180A CN 115281180 A CN115281180 A CN 115281180A CN 202210779953 A CN202210779953 A CN 202210779953A CN 115281180 A CN115281180 A CN 115281180A
- Authority
- CN
- China
- Prior art keywords
- mrna
- platelet
- stock solution
- frozen stock
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 38
- 239000011550 stock solution Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title abstract description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000243 solution Substances 0.000 claims abstract description 23
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 22
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 12
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 12
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 12
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 12
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 12
- 239000001509 sodium citrate Substances 0.000 claims abstract description 12
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 12
- 239000007983 Tris buffer Substances 0.000 claims abstract description 11
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 11
- 238000005138 cryopreservation Methods 0.000 claims description 24
- 239000002609 medium Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- 229960005261 aspartic acid Drugs 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 235000013930 proline Nutrition 0.000 claims description 4
- 229960002429 proline Drugs 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 235000004554 glutamine Nutrition 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- 235000014705 isoleucine Nutrition 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 235000005772 leucine Nutrition 0.000 claims description 2
- 229960003136 leucine Drugs 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 235000006109 methionine Nutrition 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 235000008729 phenylalanine Nutrition 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000004400 serine Nutrition 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 235000008521 threonine Nutrition 0.000 claims description 2
- 229960002898 threonine Drugs 0.000 claims description 2
- 229960004441 tyrosine Drugs 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 235000014393 valine Nutrition 0.000 claims description 2
- 229960004295 valine Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 229960002989 glutamic acid Drugs 0.000 claims 1
- 229960002743 glutamine Drugs 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 5
- 238000003860 storage Methods 0.000 abstract description 5
- 239000003550 marker Substances 0.000 abstract description 4
- 230000008827 biological function Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 2
- 229920002477 rna polymer Polymers 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 abstract description 2
- 210000001772 blood platelet Anatomy 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 108700021021 mRNA Vaccine Proteins 0.000 description 3
- 229940126582 mRNA vaccine Drugs 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 2
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010035766 P-Selectin Proteins 0.000 description 2
- 102000008212 P-Selectin Human genes 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 210000000948 non-nucleated cell Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明公开了一种mRNA‑血小板复合物冻存液及其制备方法。该冻存液包括以下组分:化学限定培养基、二甲基亚砜、人血清蛋白、海藻糖、氯化镁、甘油、tris溶液、柠檬酸钠。使用该冻存液后,与新鲜制备的mRNA‑血小板复合物相比较,冻存后复合物的完整性,表达特定标志物,以及生物学功能都相类似,能够达到低温冷冻保存的目的。该冻存液即能降低DMSO浓度,又不含动物源性血清,同时具备在深低温‑80度或‑168度液氮中保护血小板和mRNA的双重功能,该冻存液组合可直接用于下一步动物实验和临床研究。
Description
技术领域
本发明涉及生物制剂技术领域,具体涉及一种mRNA-血小板复合物冻存液及其制备方法。
背景技术
mRNA疫苗是将RNA在体外进行相关的修饰后传递至机体细胞内表达并产生蛋白抗原,从而导机体产生针对该抗原的免疫应答,进而扩大机体的免疫能力。由于mRNA自身的稳定性差、易被组织内的核酸酶降解、进入细胞的效率较低、翻译效率较低等问题,这些缺陷限制了mRNA疫苗的应用,不同的递送载体对mRNA疫苗的稳定性和翻译效率也起到非常关键的作用,递送载体可分为病毒载体和非病毒载体(包括脂质体、非脂质体、病毒、纳米颗粒等)。因此,需要一个载体,能够通过脉管系统将mRNA载入肿瘤部位。
血小板是一种小而无核的细胞,在血液循环中呈凹形、椭圆形或圆盘状,通常其直径约2-5μm,厚度约0.5μm,是血液循环中最小的细胞,人体内血小板数量为每升150-400×109个,平均循环寿命为5-7天,由于其快速补充和适当的循环时间,可避免生物载体在体内的不良积蓄,因此,可作为一种安全的生物治疗载体。目前基于血小板的肿瘤靶向治疗策略有:血小板模拟纳米载体递药策略、血小板与纳米粒(nanoparticles,NPs)结合策略以及工程化血小板靶向策略。
血小板mRNA复合物是使用血小板装载mRNA,能够保护mRNA不被血液中和,增加mRNA发挥抗肿瘤作用的一种生物制剂,使得mRNA的应用场景不止局限于瘤内注射,有了血小板的装载,可以静脉使用mRNA,导向肿瘤细胞和组织。mRNA-血小板复合物目前处于基础研发阶段,该复合物的使用一般都是现场提取血小板进行制作,会造成批次间的不稳定性,因此,亟需研发一种能够低温保存mRNA-血小板复合物,可以规模化标准化制备的保护剂,该保护剂可以在低温环境下同时保存血小板和mRNA的功能,现有血小板冻存液对血小板有保护作用,但不适用于mRNA的保存,而mRNA的保存液对血小板低温冻存又没有作用。因此,需要一种能够保证两者活性的冻存液。
发明内容
为了解决上述技术问题,本发明的目的是提供一种mRNA-血小板复合物冻存液及其制备方法,以解决现有技术无法保存mRNA-血小板复合物的问题。
本发明解决上述技术问题的技术方案如下:提供一种mRNA-血小板复合物冻存液,包括以下组分:化学限定培养基、二甲基亚砜、人血清蛋白、海藻糖、氯化镁、甘油、tris溶液和柠檬酸钠。
本发明的有益效果为:二甲基亚砜(DMSO)为临床级细胞冻存渗透性保护剂,人血清蛋白为保护该复合物的胶体渗透压,海藻糖为保护该复合物的表面稳定,柠檬酸钠抑制血小板活化,mRNA选自:mRNA、单纯疱疹病毒、麻疹病毒、慢病毒。使用该保护剂进行冻存复苏后,与新鲜制备的mRNA-血小板复合物相比,仍保持相同的外观特征,内部结构以及相同的生物学活性。
在上述技术方案的基础上,本发明还可以做如下改进:
进一步,化学限定培养基包括氨基酸、维生素、无机盐和水。
进一步,化学限定培养基、二甲基亚砜、人血清蛋白、海藻糖、氯化镁、甘油和柠檬酸钠的质量比为90-99:1-5:1-10:1-5:0.5-4:0.2-7:0.5-4。
进一步,tris溶液pH值为6.8-8.0。
进一步,氨基酸为赖氨酸、色氨酸、苯丙氨酸、甲硫氨酸、苏氨酸、异亮氨酸、亮氨酸、缬氨酸、丙氨酸、精氨酸、天门冬氨酸、胱氨酸、脯氨酸、酪氨酸、甘氨酸、、脯氨酸、丝氨酸、半胱氨酸、天冬酰胺、谷氨酰胺、天冬氨酸和谷氨酸中至少一种。
进一步,无机盐为钙、磷、钾、钠、氯、镁、硫的磷酸盐、硝酸盐、硫酸盐、碳酸盐和盐酸盐中至少一种。
本发明还提供上述mRNA-血小板复合物冻存液的制备方法,包括以下步骤:在化学限定培养基中加入二甲基亚砜、人血清蛋白、海藻糖、氯化镁、甘油、tris溶液和柠檬酸钠,制得mRNA-血小板复合物冻存液。
本发明还提供上述mRNA-血小板复合物冻存液在mRNA-血小板复合物保存方面的应用。
本发明具有以下有益效果:使用该冻存液后,与新鲜制备的mRNA-血小板复合物相比较,冻存后复合物的完整性,表达特定标志物,以及生物学功能都相类似,能够达到低温冷冻保存的目的。该冻存液即能降低DMSO浓度,又不含动物源性血清,同时具备在深低温-80度或-168度液氮中保护血小板和mRNA的双重功能,该冻存液组合可直接用于下一步动物实验和临床研究。
附图说明
图1为mRNA-血小板复合物冻存前后荧光显微镜外观图;
图2为mRNA-血小板复合物冻存前后扫描电子显微镜图;
图3为mRNA-血小板复合物冻存前后透射电子显微镜图;
图4为mRNA-血小板复合物冻存前后血小板表面标记物CD62表达情况;
图5为mRNA-血小板复合物冻存前后血小板平均分布宽度图;
图6为mRNA-血小板复合物冻存前后细胞杀伤功能图;
图7为mRNA-血小板复合物冻存前后动物实验降低肿瘤转移功能图。
具体实施方式
以下结合附图对本发明的原理和特征进行描述,所举实例只用于解释本发明,并非用于限定本发明的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
实施例1:
冻存液的制备:冻存液主要成分如下:化学限定培养基的质量体积比为80~99%,二甲基亚砜(DMSO)的体积百分数1-5%,人血清蛋白1-10%、海藻糖1-5%、氯化镁0.5-4%、甘油0.2-7%、tris溶液Ph6.8-8.0、柠檬酸钠0.5-4%。
具体操作如下:在生物安全柜无菌环境中取4℃保存的化学限定培养基80-100份,水浴环境下升温至室温;在生物安全柜无菌环境中取二甲基亚砜1-5份;人血清蛋白1-10份、海藻糖1-5份、氯化镁0.5-4份、甘油0.2-7份、tris溶液Ph6.8-8.0 10-50份、柠檬酸钠0.5-4份,在常温、安全柜无菌环境中混合化学限定培养基和二甲基亚砜、人血清蛋白、海藻糖、氯化镁、甘油、tris溶液Ph6.8-8.0、柠檬酸钠,配置成终浓度为含80-99%化学限定培养基及1-5%二甲基亚砜、人血清蛋白1-10%、海藻糖1-5%、氯化镁0.5-4%、甘油0.2-7%、tris溶液Ph6.8-8.0、柠檬酸钠0.5-4%、的冻存液。冻存液制备成100-500ml体积放置常温或4度冰箱待用。
血小板的制备:从小鼠全血中分离血小板。C57小鼠(眶窦)采集全血放入用乙二胺四乙酸二钾处理的试管中。室温下全血100g离心20min,收集富血小板血浆(PRP)。此后,将PGE1以1μM的最终浓度添加到PRP中,并将PRP在100g下再离心20min以进一步去除红细胞。分离血小板:将PRP在800g下离心20分钟。收集沉淀并将其重新悬浮在含有1μM PGE1的台式液中。从小鼠体内采集约20-25ml血液,每次分离约1010个血小板。血小板以每100μl台式液1×108血小板的浓度在含有1μM PGE1的1ml台式液中再悬浮。对于血小板的体外活化,将血小板溶液以800g离心20分钟,然后重悬到台式缓冲液中以进行后面的活化实验。在显微镜下用血小板仪计数血小板数量。
血小板mRNA复合物的制备:在体外不活化血小板的状态下,对血小板进行mRNA的装载,在血小板与mRNA不同的MOI比值下,检测血小板装载mRNA的饱和比值,以此为依据,确定后面细胞实验、动物实验制备血小板-mRNA复合物时两者的最佳比例。通过qPCR检测装载效率,平均每个血小板可以装载6-8个mRNA;通过扫描电子显微镜下可以看出,装载mRNA后两种血小板外观无差别;通过透射电子显微镜可以看出,血小板在体外能够将mRNA吞入。
冻存液的使用:计数取血小板-mRNA复合物1-100×1011个,在PRP 800g下离心20分钟。收集沉淀并将其重新悬浮在血小板-mRNA复合物冻存液100-10000ul中,每个500ul体系分装到冻存管中,
冻存管置于已处于常温状态的程序降温盒中,再将程序降温盒放置于-80℃超低温冰箱过夜,第二天转移至液氮罐冻存架中保存,备用。
复苏:将-80度或液氮中保存的血小板-mRNA复合物放至水浴锅中复苏,水浴锅调整温度20度-37度。看到溶液化开,进行下一步的实验。
试验例
一、mRNA-血小板复合物冻存前,冻存后荧光显微镜外观检测,血小板染绿色荧光标记的CD41抗体,冻存前,冻存后。使用荧光显微镜观测两者表达CD41特异性血小板抗体的情况。使用冻存液在-198度液氮中冻存一周后,复苏观察,与新鲜制备的mRNA-血小板复合物表达血小板特异性抗体CD41一致。结果见图1。
二、mRNA-血小板复合物冻存前,冻存后扫描电子显微镜图,mRNA-血小板复合物体积较小,只有2ul左右,普通光学显微镜下只能观察冻存前后轮廓,想要观察表面变化需要在放大倍数更高的扫描电镜下,无论血小板处于聚集状态或单个状态,冻存复苏后和新鲜制备的mRNA-血小板复合物,两者状态一致。结果见图2。
三、mRNA-血小板复合物冻存前,冻存后透射电子显微镜图,观察扫描电镜后,如果观察内部结构,观察经过冻存后,mRNA和血小板是否还在一起,需要做透射电镜,经过超薄切片切开mRNA-血小板复合物后,发现在冻存前和冻存后,血小板都会将mRNA包裹,箭头所指。结果见图3。
四、mRNA-血小板复合物冻存前,冻存后检测血小板表面标记物CD62表达情况。
流式细胞仪检测,在没有经过凝血酶刺激的条件下,正常血小板与装载mRNA的血小板P选择素的表达都几乎为0;经过凝血酶刺激后,正常血小板与装载mRNA的血小板P选择素的表达,在短时刺激15min时,都是10%左右,在长时刺激时,都是增加到约45%,说明装载mRNA的血小板与正常血小板一样,保持着生物学功能的完好,而且经过比较,冻存复苏后mRNA-血小板复合物和新鲜制备的表达趋势都是一致。结果见图4
五、mRNA-血小板复合物冻存前,冻存后血小板平均分布宽度图,两者一致。血小板平均分布宽度也能反应血小板异常,经过血常规检测,发现冻存前后两者一致,说明该冻存液能够在深低温下保护血小板。结果见图5。
六、mRNA-血小板复合物冻存前,冻存后还具备细胞杀伤功能图,装载了mRNA的血小板,与肿瘤细胞结合,并将表达绿色荧光的mRNA带入肿瘤细胞内,并在MOI=5时,已经显示出对4T1细胞的杀伤活性,证明了装载有mRNA的血小板,能够将mRNA载入肿瘤细胞,引起肿瘤细胞裂解。比较冻存前后mRNA-血小板复合物杀伤活性,发现两者基本一致,说明该冻存液能够很好地保护血小板功能,又能很好的保护mRNA功能。结果见图6。
七、为mRNA-血小板复合物冻存前,冻存后动物实验降低肿瘤转移功能图。给小鼠接种4T1,一种高转移性乳腺癌细胞,对照组25天后肺部长满结节,使用现场制作和冻存后的血小板-mRNA复合物进行治疗,发现两者都能显著降低小鼠肺转移结节。结果见图7。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (8)
1.一种mRNA-血小板复合物冻存液,其特征在于,包括以下组分:化学限定培养基、二甲基亚砜、人血清蛋白、海藻糖、氯化镁、甘油、tris溶液和柠檬酸钠。
2.根据权利要求1所述的mRNA-血小板复合物冻存液,其特征在于,所述化学限定培养基包括氨基酸、维生素、无机盐和水。
3.根据权利要求1所述的mRNA-血小板复合物冻存液,其特征在于,所述化学限定培养基、二甲基亚砜、人血清蛋白、海藻糖、氯化镁、甘油和柠檬酸钠的质量比为90-99:1-5:1-10:1-5:0.5-4:0.2-7:0.5-4。
4.根据权利要求1所述的mRNA-血小板复合物冻存液,其特征在于,所述tris溶液pH值为6.8-8.0。
5.根据权利要求2所述的mRNA-血小板复合物冻存液,其特征在于,所述氨基酸为赖氨酸、色氨酸、苯丙氨酸、甲硫氨酸、苏氨酸、异亮氨酸、亮氨酸、缬氨酸、丙氨酸、精氨酸、天门冬氨酸、胱氨酸、脯氨酸、酪氨酸、甘氨酸、、脯氨酸、丝氨酸、半胱氨酸、天冬酰胺、谷氨酰胺、天冬氨酸和谷氨酸中至少一种。
6.根据权利要求2所述的mRNA-血小板复合物冻存液,其特征在于,所述无机盐为钙、磷、钾、钠、氯、镁、硫的磷酸盐、硝酸盐、硫酸盐、碳酸盐和盐酸盐中至少一种。
7.根据权利要求1-5任一项所述的mRNA-血小板复合物冻存液的制备方法,其特征在于,包括以下步骤:在化学限定培养基中加入二甲基亚砜、人血清蛋白、海藻糖、氯化镁、甘油、tris溶液和柠檬酸钠,制得mRNA-血小板复合物冻存液。
8.权利要求1-5任一项所述的mRNA-血小板复合物冻存液在mRNA-血小板复合物保存方面的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210779953.7A CN115281180A (zh) | 2022-07-04 | 2022-07-04 | 一种mRNA-血小板复合物冻存液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210779953.7A CN115281180A (zh) | 2022-07-04 | 2022-07-04 | 一种mRNA-血小板复合物冻存液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115281180A true CN115281180A (zh) | 2022-11-04 |
Family
ID=83822187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210779953.7A Withdrawn CN115281180A (zh) | 2022-07-04 | 2022-07-04 | 一种mRNA-血小板复合物冻存液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115281180A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105123671A (zh) * | 2015-07-24 | 2015-12-09 | 广州赛莱拉干细胞科技股份有限公司 | 一种细胞冻存液、应用及免疫细胞冻存方法 |
CN108450458A (zh) * | 2018-03-27 | 2018-08-28 | 成都菱祐生物科技有限公司 | 一种无血清细胞冻存液 |
CN109526941A (zh) * | 2018-12-27 | 2019-03-29 | 广州赛莱拉干细胞科技股份有限公司 | 一种脂肪间充质干细胞的保存液 |
CN113557295A (zh) * | 2019-03-15 | 2021-10-26 | 株式会社美加细胞 | 哺乳动物细胞的保存液 |
CN114041455A (zh) * | 2021-12-01 | 2022-02-15 | 东莞再立健生物科技有限公司 | 一种干细胞冻存液、其制备方法及应用 |
CN115119829A (zh) * | 2017-10-19 | 2022-09-30 | 斯特雷克股份有限公司 | 用于胞外囊泡的溶血和凝血调节以及稳定化的组合物 |
-
2022
- 2022-07-04 CN CN202210779953.7A patent/CN115281180A/zh not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105123671A (zh) * | 2015-07-24 | 2015-12-09 | 广州赛莱拉干细胞科技股份有限公司 | 一种细胞冻存液、应用及免疫细胞冻存方法 |
CN115119829A (zh) * | 2017-10-19 | 2022-09-30 | 斯特雷克股份有限公司 | 用于胞外囊泡的溶血和凝血调节以及稳定化的组合物 |
CN108450458A (zh) * | 2018-03-27 | 2018-08-28 | 成都菱祐生物科技有限公司 | 一种无血清细胞冻存液 |
CN109526941A (zh) * | 2018-12-27 | 2019-03-29 | 广州赛莱拉干细胞科技股份有限公司 | 一种脂肪间充质干细胞的保存液 |
CN113557295A (zh) * | 2019-03-15 | 2021-10-26 | 株式会社美加细胞 | 哺乳动物细胞的保存液 |
CN114041455A (zh) * | 2021-12-01 | 2022-02-15 | 东莞再立健生物科技有限公司 | 一种干细胞冻存液、其制备方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11458170B2 (en) | Pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor | |
JP4620192B2 (ja) | 赤血球内に生物学的活性薬剤をカプセル内封入する方法およびそのための装置 | |
CN108235981B (zh) | 一种可临床使用的细胞冻存液 | |
AU2006238917C1 (en) | Erythrocytes containing arginine deiminase | |
Hamidi et al. | Carrier erythrocytes: an overview | |
JP2018141002A (ja) | 削減された残存血漿容積を有する血小板濃縮物を提供するための自動化方法とシステムおよびそのような血小板濃縮物のための貯蔵媒体 | |
JPS61502750A (ja) | 赤血球の長期間保存 | |
JPH0751498B2 (ja) | 赤血球中への生化学的活性物質をカプセル化する方法とその装置 | |
Kumarl et al. | Resealed erythrocytes as a carrier for drug targeting: a review | |
CN113812395A (zh) | 一种红细胞保存液 | |
CN115281180A (zh) | 一种mRNA-血小板复合物冻存液及其制备方法 | |
Gopal et al. | Effective drug targeting by erythrocytes as carrier systems | |
WO2020227843A1 (zh) | 临床细胞制剂用保存液的配方和用途 | |
US8043610B2 (en) | Freeze-dried composition of inactivated virus envelope with membrane fusion activity | |
CN114342919B (zh) | 一种nk细胞保护运输液 | |
van Bruggen et al. | Prevention of non-immune mediated transfusion-related acute lung injury; from blood bank to patient | |
CN114258910A (zh) | 一种可输注细胞冻存液及其应用 | |
Valeri et al. | Viability and function of outdated human red blood cells after biochemical modification to improve oxygen transport function, freezing, thawing, washing, postthaw storage at 4 C, perfusion in vitro through a bubble oxygenator, and autotransfusion | |
Jadhav et al. | DRUG, ENZYM E AND PEPTIDE DELIVERY USING ERYTHROCYTES AS DRUG CARRIER | |
CN118415161A (zh) | 一种改良的含有d-海藻糖的红细胞冷冻保护剂及其制备方法与应用 | |
CN117481108A (zh) | 一种car-t细胞冻存制剂 | |
KR20110062812A (ko) | 고농도 인간유래세포의 동결을 위한 백과 그를 이용한 동결 및 해동 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20221104 |